Prasterone enanthate

Prasterone enanthate
Clinical data
Trade names Gynodian Depot (with estradiol valerate)
Synonyms DHEA enanthate; Prasterone heptanoate; DHEA heptanoate; DHEA-E; EDHEA; SH-70833 (with EV); Androst-5-en-3β-ol-17-one 3β-heptanoate
Routes of
administration		 Intramuscular injection
Drug class Androgen; Anabolic steroid; Androgen ester; Estrogen; Neurosteroid
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Duration of action 18 days[1]
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C26H40O3
Molar mass 400.60 g·mol−1
3D model (JSmol)

Prasterone enanthate (also known as prasterone heptanoate, dehydroepiandrosterone enanthate, DHEA enanthate, DHEA-E, or androst-5-en-3β-ol-17-one 3β-heptanoate) is a synthetic, injected, long-lasting ester prodrug[1] of dehydroepiandrosterone (DHEA), a weak androgen and neurosteroid.[2][3][4] It is a component of Gynodian Depot, a combination formulation of 4 mg estradiol valerate and 200 mg prasterone enanthate in oil for depot intramuscular injection that is used in the treatment of menopausal symptoms and is marketed in Europe and South America.[5][6][7][8][9][10] Prasterone enanthate has an average duration of 18 days in this formulation.[1] The pharmacokinetics of the formulation have also been assessed in other studies.[1] The drug was patented, by Schering, in 1971.[3]

See also

References

  1. 1 2 3 4 Düsterberg B, Wendt H (1983). "Plasma levels of dehydroepiandrosterone and 17 beta-estradiol after intramuscular administration of Gynodian-Depot in 3 women". Horm. Res. 17 (2): 84–9. PMID 6220949.
  2. ↑ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 641–. ISBN 978-1-4757-2085-3.
  3. 1 2 William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 1208–. ISBN 978-0-8155-1856-3.
  4. ↑ John W. Blunt; Murray H. G. Munro (19 September 2007). Dictionary of Marine Natural Products with CD-ROM. CRC Press. pp. 1075–. ISBN 978-0-8493-8217-8.
  5. ↑ https://www.drugs.com/international/gynodian-depot.html
  6. ↑ J. Horsky; J. Presl (6 December 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 146–. ISBN 978-94-009-8195-9.
  7. ↑ D. Platt (6 December 2012). Geriatrics 3: Gynecology · Orthopaedics · Anesthesiology · Surgery · Otorhinolaryngology · Ophthalmology · Dermatology. Springer Science & Business Media. pp. 6–. ISBN 978-3-642-68976-5.
  8. ↑ S. Campbell (6 December 2012). The Management of the Menopause & Post-Menopausal Years: The Proceedings of the International Symposium held in London 24–26 November 1975 Arranged by the Institute of Obstetrics and Gynaecology, The University of London. Springer Science & Business Media. pp. 395–. ISBN 978-94-011-6165-7.
  9. ↑ Carrie Bagatell; William J. Bremner (27 May 2003). Androgens in Health and Disease. Springer Science & Business Media. pp. 277–. ISBN 978-1-59259-388-0.
  10. ↑ Frigo P, Eppel W, Asseryanis E, Sator M, Golaszewski T, Gruber D, Lang C, Huber J (1995). "The effects of hormone substitution in depot form on the uterus in a group of 50 perimenopausal women--a vaginosonographic study". Maturitas. 21 (3): 221–5. PMID 7616871.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.